Euphorbia dioeca Kunth as a novel source for -glucosidase inhibitors by CRISTIANS, Sol et al.
  
© 2015  
Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas 14 (6): 483 - 490 
ISSN 0717 7917 
www.blacpma.usach.cl 
 
 
Artículo Original | Original Article 
483 
 
 
Euphorbia dioeca Kunth as a novel source for -glucosidase inhibitors 
 
[Euphorbia dioeca Kunth como una nueva fuente de inhibidores de -glucosidasa] 
 
Sol CRISTIANS
1
, H. Reyna OSUNA-FERNÁNDEZ
1
, Guillermo RAMÍREZ-ÁVILA
2
,  
Verónica MUÑÓZ-OCOTERO
3
, Guillermo LAGUNA-HERNÁNDEZ
1
 & Alicia E. BRECHÚ-FRANCO
1
 
 
1Laboratorio de Estructura y Fisiología de Plantas, Departamento de Ecología y Recursos Naturales, Facultad de Ciencias, Universidad 
Nacional Autónoma de México, Distirito Federal, México 
2Centro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social, Xochitepec, Morelos, México. 
3Laboratorio de Fitoquímica, Departamento de Ecología y Recursos Naturales, Facultad de Ciencias,  
Universidad Nacional Autónoma de México, Distirito Federal, México. 
Contactos | Contacts: Sol CRISTIANS - E-mail address: scristians@ciencias.unam.mx 
 
 
 
Abstract: Euphorbia dioeca Kunth belongs to the Wanderer’s herb complex that is traditionally used for skin diseases and recently as 
antidiabetic. The methanol and aqueous extracts were evaluated for their in vitro -glucosidase inhibitory activity and an oral starch 
tolerance test. These extracts showed an IC50 of 0.55 and 0.85 mg/mL, respectively. In diabetic Long Evans rats, the methanol and aqueous 
extracts reduced significantly the postprandial hyperglycemia peak in 15.2% and 12.8%, respectively. The -glucosidase inhibitory activity 
is related with the presence of glycosides, phenolic compounds and flavonoids. Additionally, the safety parameters of both extracts were 
assessed by means of an acute toxicity test, being classified as innocuous. The traditional use of E. dioeca to control type 2 diabetes was 
confirmed, being an important source of -glucosidase inhibitors. 
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Resumen: Euphorbia dioeca Kunth, pertenece al complejo de plantas medicinales denominado Hierba de la Golondrina; el cual se utiliza 
para diversos padecimientos, destacando su uso como antidiabético. En dicho marco, se evaluó tanto la actividad inhibitoria de -
glucosidasa in vitro, como su desempeño en una prueba de tolerancia a una carga de almidón postprandial. Los extractos inhibieron la 
actividad de la -glucosidasa con una CI50 de 0.55 y 0.85 mg/mL, respectivamente. Los extractos metanólico y acuoso disminuyeron 
significativamente el pico hiperglucémico postprandial en un 15.2% y un 12.8%, respectivamente, cuando se evaluó en ratas diabéticas. La 
actividad inhibitoria de -glucosidasa, reflejada en ambas pruebas, está relacionada con la presencia de glicósidos, compuestos fenólicos y 
flavonoides. De manera adicional, ambos extractos fueron evaluados en una prueba de toxicidad aguda, siendo clasificados como inocuos. 
Se corroboró el uso tradicional de E. dioeca para el control de la diabetes tipo 2, siendo una importante fuente de compuestos inhibidores de 
-glucosidasa. 
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INTRODUCTION 
Type-2 diabetes mellitus (T2DM) is a polygenic 
disease characterized by a state of glucose intolerance 
associated with insulin resistance (multiple 
deficiencies in insulin action in muscular, adipose or 
hepatic tissues) and relative insulin deficiency due to 
pancreatic -cell failure (El-Kaissi & Sherbeeni, 
2011; Israili, 2011).
.
In addition, complications from 
T2DM, such as cardiovascular disease, peripheral 
vascular disease, stroke, diabetic neuropathy, 
amputation, renal failure, and blindness result in 
increasing disability and reduced life expectancy 
(Israili, 2011). 
There are 346 million people worldwide with 
diabetes. In high-income countries, diabetes primarily 
affects people over 50 years of age. But in middle-
income countries, as Mexico, the highest prevalence 
is in the most productive age groups. This trend will 
put a huge pressure on healthcare systems and 
governments expenditure (Scully, 2012). 
The pharmacological strategy for the control 
of T2DM has focused on increasing insulin levels by 
oral secretagogues that promote insulin secretion (e.g. 
sulfonylureas), improving tissue sensitivity with an 
insulin sensitizer (e.g. metformin or 
thiazolidinediones), enhancing the incretins activity 
(e.g. glucagon-peptide-1 mimetic), or reducing the 
rate of carbohydrate absorption from the 
gastrointestinal tract (e.g. -glucosidase inhibitors) 
(El-Kaissi & Sherbeeni, 2011; Israili, 2011). 
 The -glucosidase inhibitors block the 
enzymes bounded to the brush border of the small 
intestine, which hydrolyzes complex carbohydrates 
molecules into glucose and other monosaccharides, 
leading to delayed glucose absorption and lower post-
prandial blood glucose peak (El-Kaissi & Sherbeeni, 
2011; Israili, 2011; Kumar et al., 2011). The -
glucosidase inhibitors do not affect the serum lipids, 
and do not cause hypoglycemia when used in 
monotheraphy, but may increase the risk of insulin or 
insulin-secretagogue-associated hypoglycemia in 
combination therapy. The most common side effects 
of -glucosidase inhibitors are gastrointestinal 
symptoms such as flatulence, diarrhea, and 
abdominal fullness, because the carbohydrates remain 
in the intestine and the colon where bacteria digest 
the carbohydrates releasing gases (El-Kaissi & 
Sherbeeni, 2011; Israili, 2011). 
 In Mexico, like in the rest of the world, 
T2DM had a widespread incidence. There are more 
than 6.4 million of diabetics, but the number could be 
duplicated if we consider the lack of diagnose in 
many regions (Gutiérrez et al., 2012).  
 There are several natural products with a -
glucosidase inhibitors activity, such as flavonoids, 
alkaloids, terpenoids, glycosides and phenolic 
compounds; being the plants a priceless source for 
novel compounds aimed to the control of T2DM 
(Borges de Melo et al., 2006; Wardrop & 
Waidyarachchi, 2010; Kumar et al., 2011).  
 There are 383 plant species used in Mexican 
folk medicine for the treatment of T2DM (Díaz, 
1976; Martínez, 1989; Argueta et al., 1994; Aguilar-
Contreras & Xolalpa-Molina, 2002; Andrade-Cetto & 
Heinrich, 2005; Alarcón-Aguilar & Roman-Ramos, 
2006; Romero-Cerecero et al., 2009). From these, 11 
species belong to the Euphorbiaceae family, being 
only three from the Euphorbia genus. Interestingly, 
E. postrata and E. maculata belong to the “hierba de 
la golondrina” complex (wanderer’s herb complex) 
(Alcocer, 1907); nevertheless, none of the Euphorbia 
species have pharmacological studies aimed to the 
T2DM control. 
 The wanderer’s herb complex comprises 
several species of the genus Euphorbia in the 
Euphorbiaceae family: E. anychioides, E. dioeca, E. 
hirta, E. maculata and E. postrata. The common 
features of the species belonging to this plant 
complex are: their growing as a prostrate herbs; their 
ancient use for skin diseases as dyes, scabies and 
dermathosis; and their recent use for the treatment of 
TII-DM (Alcocer, 1907; Argueta et al., 1994; 
Aguilar-Contreras & Xolalpa-Molina, 2002; 
Andrade-Cetto & Heinrich, 2005; Alarcón-Aguilar & 
Roman-Ramos, 2006). 
 Euphorbia dioeca Kunth syn. Chamaesyce 
dioeca  (Kunth) Millsp., a perennial herbaceous 
plant distributed from northern Mexico to Central 
America, was chosen to perform, for the first time 
ever, a pharmacological and a preliminary chemical 
study aimed to the discovery of new -glucosidase 
inhibitors.  
 In order to establish the safety of the plant 
material, an acute toxicity test of the crude extracts 
was performed; the antihyperglycemic activity was 
quantified by means of an oral starch tolerance test 
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and an in vitro intestinal -glucosidase inhibition test 
(Verspohl, 2002; Srinivasan & Ramarao, 2007; Fröde 
& Medeiros, 2008). Also, a preliminary 
phytochemical screening was carried out 
(Domínguez, 1973). 
 
MATERIALS AND METHODS 
Plant material 
Euphorbia dioeca Kunth (Euphorbiaceae) was 
collected in La Trocha beach, municipality of 
Alvarado, Veracruz State, Mexico, in August 2004. 
Botanical specimens were deposited in the Science 
Faculty Herbarium (FCME), National Autonomous 
University of Mexico (voucher specimens 089182 
and 089184) and the Instituto Mexicano del Seguro 
Social Herbarium (IMSSM; voucher specimen 
14967). 
 
Preparation of the extracts 
The aerial parts of the plant were dried at room 
temperature in darkness and pulverized. The crude 
extracts were obtained by means of a Soxhlet 
extraction with hexane, dichloromethane and 
methanol (Merck) (200 g  8h  3 times), the solvent 
was eliminated in vacuo. The aqueous extracts were 
prepared by maceration (200 g in 1 L) during 24 
hours, filtered, and lyophilized. 
 
Animals 
Balb/c mice between 20-25 g were used for the 
toxicity test. For the oral starch tolerance test Long 
Evans male rats between 240-250 g were used. The 
animals were housed under controlled conditions of 
temperature (25±1° C) and light (14/10h photoperiod) 
and maintained on water and food ad libitum (Rodent 
Chow 2018S, Harlan Teklad bedding). Procedures 
involving animals and their care were conducted in 
conformity with the Mexican Official Norm for 
Animal Care and Handing (NOM-062-ZOO-1999) 
and in compliance with international rules on care 
and use of laboratory animals.  
 
Preliminary phytochemical screening 
In order to detect the presence of main groups of 
secondary metabolites, glycosides (Mölish reagent), 
alkaloids (Draggendorf and silicotungstic acid), 
flavonoids (Shinoda), terpenoids (acetic anhydride-
chloroform-sulfuric acid), tannins (sodium chloride-
gelatin) and phenolic compounds (ferric chloride) 
were preliminary screened (Domínguez, 1973). 
 
Acute toxicity test  
The acute toxic category method was carried out 
following the protocol number 423 of the 
Organization for Economic Co-operation and 
Development (OECD, 2001) with the methanol and 
aqueous extracts. Three Balb/c female mice per 
extract were used. The extract was dissolved in water 
and administered orally at a dose of 6 g/kg, using an 
intragastric cannula. The mice status was evaluated 
during the each hour until 6 hours, then at 12 and 24 
hours and daily until the 14
th
 day. 
 
Alpha-glucosidase inhibition assay  
The technique was performed as described by Ortiz-
Andrade and collaborators (2007) (Ortiz-Andrade et 
al., 2007). Briefly, rat small intestine was dissected 
and flushed with 100 mL of ice-cold buffered saline 
solution. The tissue was externally cleaned, the 
mucosa exposed and scraped with a glass slide on an 
ice-cold glass surface. The material from three or 
more animals was homogenized, adjusted to 1 
mg/mL of protein by Lowry assay, aliquoted in 1.8 
mL cryotubes and stored at –25º C until used. 
The enzymatic assay employed a 0.1 M 
sodium phosphate buffer (pH 7.0) and 12.5 mg/mL of 
corn starch (S-4126, Sigma) as substrate. E. dioeca 
methanolic and aqueous extracts solutions (0.08, 
0.16, 0.4, 1.6, 4, 16 mg/mL) were added for 
inhibition measurement; water was used for 
determine the 100% of activity. Each reaction was 
initiated adding 10 L of crude enzyme and 
incubated at 37º C for 10 minutes, then stopping it 
with 12.5 g of acarbose and ice incubation; 
reactions were performed by quadruplicate.  
Released glucose was measured in triplicate, 
using the glucose oxidase method (GOD-PAP, 
GL2614, Randox) according with the manufacturer’s 
recommendations. 
The absorbance was quantified in a micro-
titer plate photometer (StatFax 2100, Awarness 
Technology, Inc.) at 492 nm, subtracting the 
absorbance at 630 nm for turbidity compensation. 
 
Experimental model of type 2 diabetes mellitus in 
male Long Evans rats 
Diabetes was induced by the suggested model of the 
Animal Models of Diabetic Complications 
Consortium (AMDCC) of the National Institutes of 
Health of the United States of America (Brosius, 
2003). 
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The animals were fasted for a period of 6 
hours before streptozocin (STZ; Axxora; 50 mg/kg) 
diabetes induction. The STZ was dissolved in a Na-
citrate buffer (pH 4.5) and was administered by 
intraperitoneal injection. Only animals with fasting 
blood glucose concentration ranging between 250-
400 mg/dL were included in the study. 
 
Oral starch tolerance test  
Four groups with eight rats each were formed: 
vehicle, methanol extract, aqueous extract and 
acarbose (Sincrosa®, 50 mg/kg). The plant extract 
(500 mg/kg), acarbose, or vehicle was first 
intragastrically administered, ten minutes later the 
animals were challenged with a cornstarch 
suspension (Sigma S-4126; 2 g/kg). Blood samples 
were taken at 0, 30, 60, 90 and 120 minutes, through 
a cut at the tip of the tail. Approximately 150 L of 
blood were collected using a heparinized capillary 
pipette. The samples were kept in 0.5 mL refrigerated 
microtubes until plasma was separated by 
centrifugation (4500 rpm  5 minutes) and recovered. 
The glycemic index was measured with a commercial 
kit (GOD-PAP, GL2614, Randox) according with the 
manufacturer’s recommendations, following the same 
procedure described in the -glucosidase inhibition 
assay. 
 
 
Table 1 
Main groups of secondary metabolites qualitative tests of E. dioeca extracts (- negative result, + lightly 
positive, ++ positive, +++ strongly positive, secondary metabolite major concentration) 
Secondary metabolite Extract Result 
 
Glycosides 
 
Hexane – 
Dichloromethane – 
Methanol 1        – 2        – 
Aqueous ++ 
 
Alkaloids (Draggendorf) 
Hexane – 
Dichloromethane – 
Methanol – 
 
Alkaloids (Silicotungstic Acid) 
Hexane – 
Dichloromethane + 
Methanol – 
Aqueous – 
 
Flavonoids 
Hexane ++ 
Dichloromethane + 
Methanol +++ 
Aqueous – 
 
Phenolic compounds 
Hexane + 
Dichloromethane – 
Methanol ++ 
Aqueous ++ 
 
Tannins 
Hexane + 
Dichloromethane + 
Methanol +++ 
Aqueous ++ 
 
Terpenes 
Hexane ++ 
Dichloromethane + 
Methanol – 
Aqueous – 
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Statistic analysis 
The analysis of variance (ANOVA) followed by 
Dunnett’s t-test for comparison with respect to 
vehicle were performed in order to evaluate the 
presence of significant differences between the 
diverse treatments, using the program STATISTICA 
6.0. 
 
RESULTS 
Preliminary phytochemical screening  
The hexane, methanol and aqueous extracts displayed 
a positive reaction to flavonoids, phenolic and tannins 
in secondary metabolites qualitative tests; 
nevertheless, the methanol and aqueous extracts of E. 
dioeca showed more intense reaction. In addition 
only the hexane extract exhibited a positive reaction 
to terpenes. It should be noted the high content of 
flavonoids in methanol extract and the presence of 
glycosides in the aqueous extract (Table 1). 
 
Acute toxicity test 
In agreement with the phytochemical results, the 
acute toxicity test was performed in order to establish 
the safety parameters of the aqueous and methanol 
extracts. The mice administered with methanol and 
aqueous extracts, even at the dose of 6 g/kg, did not 
present any physiological or behavioral disturbances. 
Accordingly to the protocol 423 of OECD, the 
extracts belong to the innocuous class. 
 
Alpha-glucosidase inhibition assay 
Tests were run with the methanol and aqueous crude 
extracts at a concentration of 2 mg/mL, for 
comparison with other plant species; these extracts 
inhibited the -glucosidase activity in 79% and 57% 
respectively; further pharmacological characteriza-
tion was scheduled for the most active preparations. 
The dose-response curves were obtained in a wide 
range of concentrations (16, 4, 1.6, 0.4, 0.16, and 
0.08 mg/mL). The IC50 values were calculated as 0.55 
and 0.85 mg/mL for methanol and aqueous extracts 
(Table 2, Figure 1). 
 
Table 2 
Alpha-glucosidase inhibitory effect of E. dioeca methanolic and aqueous extracts.  
Each measure was performed by quadruplicate. 
 -glucosidase inhibitory effect (%)  
Extract (mg/mL) 0.08  0.16  0.4 1.6  4  16  IC50 (mg/mL) 
Methanolic  
14 27.82 42.79 77.54 93.96 96.64 0.55  
Aqueous  
25.66 32.51 38.65 59.88 76.20 88.82 0.85 
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Figure 1 
Concentration-response curve of -glucosidase inhibitory effect of E. dioeca methanolic and aqueous 
extracts. Each value is the mean ± SEM for four independent repetitions of respectively concentration. 
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Oral starch tolerance test 
Once the high inhibition of intestinal glucosidases 
was shown in rat intestinal preparations, the in vivo 
activity of the extracts was tested in the model of oral 
starch tolerance curve in STZ-diabetic rats. The 
methanol and aqueous extracts reduced the 
postprandial hyperglycemia peaks in 15.2% and 
12.8% respectively (Figure 2). 
 
 
Figure 2 
Oral starch tolerance curve for E. dioeca methanolic and aqueous extracts (500 mg/kg) in STZ-diabetic Long 
Evans rats (2 g/kg; each value is the mean ± SEM for 8 rats in each group *p < 0.05 signiﬁcantly different 
ANOVA followed by Dunnett’s t-test for comparison with respect to vehicle at the same time). 
 
DISCUSSION 
The antidiabetic activity of a medicinal plant can be 
explained from various pharmacological approaches, 
in the case of E. dioeca, the inhibitory activity of -
glucosidase is, at least, one of the mechanisms that 
allow us to confirm its traditional use. 
α-Glucosidase is membrane-bound enzyme 
of the GH31 family that hydrolyzes larger 
carbohydrate molecules to glucose and related 
monosacharides. Most of these enzymes are located 
in the brush border of the small intestine where they 
catalyze the final step in the digestive process of 
carbohydrates. Hence, α-glucosidases inhibitors can 
delay the liberation of glucose from dietary complex 
carbohydrates, retarding glucose absorption and 
lowering the postprandial blood glucose peak, being a 
useful pharmacological tool aimed to prevent the 
progression of the disease and for treating pre-
diabetic conditions (El-Kaissi & Sherbeeni, 2011). 
The best-known α-glucosidase inhibitors are 
acarbose and miglitol; the former is a natural product 
isolated initially from an Actinoplanes strain, and the 
second is the N-hydroxyethyl analogue of 1-
deoxynojirimycin, isolated from Morus spp. (Borges 
de Melo et al., 2006; El-Kaissi & Sherbeeni, 2011; 
Israili, 2011). 
The highest -glucosidase inhibitory activity 
of the methanol extract showed in the in vitro 
inhibition assay and the oral starch tolerance curve 
(Table 2, Figures 1 and 2), is in agreement with the 
chemical composition. A report of Euphorbia 
drummondii, demonstrates that the highest amount of 
phenolic compounds is related with their -
glucosidase inhibitory activity (Gulati et al., 2012). 
This biological activity could be explained with the 
role of phenolic compounds as antioxidants, and its 
relation in diabetes prevention and control (Borges de 
Melo et al., 2006; Wardrop & Waidyarachchi, 2010; 
Kumar et al., 2011; Aboul-Enein et al., 2013; Gulcin 
& Beydemir, 2013; van Dam et al., 2013).  
In addition, the high content of flavonoids in 
the methanol extract could be associated with the 
lowest -glucosidase inhibitory EC50 and the highest 
reduction of the postprandial hyperglycemia peak. 
The reports of -glucosidase inhibitory activity 
exerted by the isolated flavonoids from Euphorbia 
humifusa extracts (Kang et al., 2012), as well as 
several flavones reported in Origanum majorana 
(Borges de Melo et al., 2006), support the importance 
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of the chemical composition of E. dioeca methanol 
extract, showing their value as an aid for decrease the 
postprandial hyperglycemia, involved in the 
mechanism of type 2 diabetes mellitus and its 
complications (Wardrop & Waidyarachchi, 2010; El-
Kaissi & Sherbeeni, 2011; Israili, 2011; Kumar et al., 
2011). 
Nevertheless, the aqueous extract had a 
complex phytochemical composition, the presence of 
glycosides in this extract indicate that different 
compounds mediate the -glucosidase inhibitory 
activity; being acarbose and miglitol the most 
outstanding examples of this group of inhibitors 
(Borges de Melo et al., 2006). 
Additionally, the active extracts of E. dioeca 
fulfill the safety parameters, since the acute toxicity 
test reveals that the methanol and aqueous extracts of 
E. dioeca, were innocuous (OECD, 2001) this result 
may be related to the absence of alkaloids and 
terpenes, secondary metabolites frequently associated 
to the toxic properties (Bruneton, 2001; Gershenzon 
& Dudareva, 2007). 
 
CONCLUSION 
To conclude, E. dioeca methanol and aqueous 
extracts showed strong capabilities as an aid to 
control type 2 diabetes mellitus, by the reduction of 
the postprandial hyperglycemia peak; their action is 
mediated, at least, through the -glucosidase 
inhibition. The biological activity is related with the 
presence of glycosides, phenolic compounds and 
flavonoids. This study provides pharmacological and 
chemical evidence for the popular use of the 
wanderer’s herb complex for the treatment of 
diabetes; however, future phytochemical studies 
focused in the isolation and identification of the 
pharmacologically active compounds are required for 
the standardization and description of the antidiabetic 
mode of action.  
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